Low-dose aspirin is widely used by individuals to prevent first myocardial infarction and stroke. Although many health care professionals and patients believe that aspirin is safe and effective, the evidence is far from conclusive. As a result, current practice guidelines are inconsistent and leave practitioners with many unanswered questions. Because aspirin is available without prescription, pharmacists may often be the only health care professional positioned to advise and educate the patient.
Get full access to this article
View all access options for this article.
References
1.
US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med. 2002;136:157–160.
2.
WolffT, MillerT, KoS.Aspirin for the primary prevention of cardiovascular events: An update of the evidence for the US Prevention Services Task Force. Ann Intern Med. 2009;150:405–410.
3.
RidkerPM, CookNR, LeeIM, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–1304.
4.
KolburMR, KorownykC.An aspirin a day? Aspirin use across a spectrum of risk: Cardiovascular disease, cancers and bleeds [editorial]. Expert Opin Pharmacother. 2014;15:153–157.
5.
BelchJ, MacCuishA, CampbellI, The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) Trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
6.
OgawaH, NakayamaM, MorimotoT, ; for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA. 2008;300:2134–2141.
7.
EthierJ, Bragg-GreshamJL, PieraL, Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50:602–611.
8.
FowkesFGR, PriceJF, StewartMC, for the Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a population screened for a low ankle brachial index. JAMA. 2010;303:841–848.
9.
Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849–1860.
10.
BartolucciAA, TenderaM, HowardG.Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796–1801.
11.
SeshasaiSR, WijesuriyaS, SivakumaranR, Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209–216.
12.
FlemingT, NissenSE, BorerJS, ArmstrongPW. Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8–9, 2003, Gaithersburg, MD. Circulation2004;109:e9004–e9005.
VandvikPO, LincoffM, GoreJM, Primary and secondary prevention of cardiovascular disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;(Suppl): e637S–e668S.
15.
PerkJ, De BackerG, GohlkeH, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–1701.
16.
BellAD, RoussinA, CartierR, The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2011;27:S1–29.
17.
BishopricNH. Toward a genomic definition of aspirin resistance. J Am Coll Cardiol. 2013;62:1277–1279.
18.
WurtzM, KristensenSD, HvasAM, GroveEL. Pharmacogenetics of the antiplatelet effect of aspirin. Curr Pharm Des. 2012;18:5294–5308.
19.
VooraD, CyrD, LucasJ, Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol. 2013;62:1267–1276.
20.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308: 81–106.
21.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71–86.
22.
SheridanS, PignoneM, MulrowC.Framingham-based tools to calculate the global risk of coronary heart disease: A systematic review of tools for clinicians. J Gen Intern Med. 2003;12:1039–1052.
23.
Risk assessment tool for estimating your 10-year risk of having a heart attack. http://cvdrisk.nhlbi.nih.gov/. Accessed March 15, 2014.
24.
HissettJ, FolksB, CoombsL, Effects of changing guidelines on prescribing aspirin for primary prevention of cardiovascular events. J Am Board Fam Med. 2014;27:78–86.
25.
FocksJJ, TielemansMM, van RossumLG, Gastrointestinal symptoms in low-dose aspirin users: A comparison between plain and buffered aspirin. Neth Heart J. 2014;22:107–112.
26.
de AbajoFJ, RodriguezLA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations [published online ahead of print February 13, 2001]. BMC Clin Pharmacol.
27.
PignoneM, AndersonGK, BinnsK, Aspirin use among adults aged 40 and older in the United States: Results of a national survey. Am J Prev Med. 2007;32(5):403–473.
